ARCHIVES

Itri Pays Fine, Agrees Not to Serve As Company Officer for Five Years

This article is from The Cancer Letter archive.

Vol. 40 No. 17 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

USLA’’s Steckel Asks More Centers Staff, Strict Enforcement of Guidelines

February 17, 1978

Abraxane Improves Progression-Free Survival Compared to Decarbazine In Stage IV Disease

November 30, 2012

Folic Acid, Vitamins B6 and 12 Do Not Affect Colorectal Adenoma Risk

October 26, 2012

Young Investigators Hold Their Own

September 28, 1979

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

November 7, 2003

Lilly Suspends Phase III Trial Of Tasisulam in Melanoma

January 28, 2011